Status:
RECRUITING
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
Lead Sponsor:
Kang Stem Biotech Co., Ltd.
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
19-80 years
Brief Summary
Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj(K0202)
Detailed Description
A Multi-center, Open, Long-term Follow-up Study to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid arthritis: 5-year Results From the K0202 Extensio...
Eligibility Criteria
Inclusion
- Subject who enrolled K0202 Clinical Trial(parent study) and has been given more than one medication.
- Subjects who understand and voluntarily sign an informed consent form
Exclusion
- 1\. Any other condition which the investigator judges would make patient unsuitable for study participation
Key Trial Info
Start Date :
October 2 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 11 2026
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04134169
Start Date
October 2 2019
End Date
April 11 2026
Last Update
October 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul national University Boramae medical center
Seoul, South Korea